Can-Fite BioPharma Ltd.
TASECan-Fite BioPharma heads into the week with short sellers in full retreat — a dramatic reversal from a peak that coincided almost exactly with its most important clinical readout in years. The positioning story over the past fortnight has been striking. Short interest climbed from under 0.5% of the free float in late April to a peak of nearly 13% on May 5 — a 25-fold increase in…
Snapshot as of 28 Jun 2026
Can-Fite BioPharma heads into the week with short sellers in full retreat — a dramatic reversal from a peak that coincided almost exactly with its most important clinical readout in years. The positioning story over…
Can-Fite BioPharma delivered the most significant clinical readout of its recent history today — but the stock heads into the weekend carrying a month of losses and a market cap of just $6.4 million, making every data…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CANF — free to start on ORTEX.
Sign up for free →Open CANF on ORTEX